Joon Oh Park

机构：Samsung Medical Center, Sungkyunkwan University · ORCID：0000-0001-6502-2612

发表论文 553 篇 · 总被引 30596 次 · h-index 73

代表论文

• Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study (2024 · ˜The œLancet. Gastroenterology & hepatology · 被引 298)
• Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study (2024 · The Lancet Oncology · 被引 118)
• Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study (2024 · Journal of Clinical Oncology · 被引 92)
• Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC). (2024 · Journal of Clinical Oncology · 被引 46)
• Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial (2024 · Journal of Clinical Oncology · 被引 37)
• Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial (2024 · Hepatology · 被引 28)